Exopolysaccharide of <i>Shigella sonnei </i>bacteria, method for producing same, vaccine and phamaceutical composition containing same

摘要

For the first time, an O-specific polysaccharide antigen that is a Shigella sonnei, phase I, exopolysaccharide has been produced and characterized, said exopolysaccharide being an authentic natural compound in the form of a bacterial capsular polysaccharide. The exopolysaccharide contains a non-toxic lipid component, namely non-hydroxylated fatty acids, and exhibits low pyrogenicity and high immunogenicity. Effective, highly specific and safe vaccines for the prophylaxis and/or treatment of Shigella sonnei shigellosis are developed on the basis of the above-mentioned exopolysaccharide, as well as pharmaceutical compositions with a broad spectrum of action, in particular, in modulating immune response.

主权项

1. A pharmaceutical composition, comprising: an effective amount of a polysaccharide, the polysaccharide being Shigella sonnei, phase I polysaccharide, comprising: 1-100 repeating disaccharide units of O-[4-amino-2-(N-acetyl)amino-2,4-dideoxy-β-D-galactopyranosyl]-(1→4)-O-[2-(N-acetyl)amino-2-deoxy-α-L-altrpyranuronic acid] linked within the polysaccharide chain by (1→3) bonds, produced using S. sonnei bacteria, but without using lipopolysaccharides as a source of production, further comprising non-hydroxylated fatty acids.